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Abstract 
 
Objective: The therapeutic alliance between patient and therapist has demonstrated an 
association with favorable psychotherapeutic outcomes in the treatment of eating disorders 
(EDs). However, questions remain about the inter-relationships between early alliance, early 
symptom improvement, and treatment outcome. We conducted a meta-analysis on the relations 
among these constructs, and possible moderators of these relations, in psychosocial treatments 
for EDs.  Method: Twenty studies met inclusion criteria and supplied sufficient supplementary 
data. Results: Results revealed small-to-moderate effect sizes, ȕs = .13 to .22 (p < .05), 
indicating that early symptom improvement was related to subsequent alliance quality and that 
alliance ratings also were related to subsequent symptom reduction. The relationship between 
early alliance and treatment outcome was partially accounted for by early symptom 
improvement. With regard to moderators, early alliance showed weaker associations with 
outcome in therapies with a strong behavioral component relative to non-behavioral therapies. 
However, alliance showed stronger relations to outcome for younger (versus older) patients, over 
and above the variance shared with early symptom improvement. Discussion: In sum, early 
symptom reduction enhances therapeutic alliance and treatment outcome in EDs, but early 
alliance may require specific attention for younger patients and for those receiving non-
behaviorally-oriented treatments. 
 
Keywords: eating disorder, meta-analysis, therapeutic alliance, treatment outcome 
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A Meta-Analysis of the Relation between Therapeutic Alliance and Outcome in Eating Disorders  
 
Therapeutic alliance, defined as the collaborative working relationship between patient 
and therapist, is one of the most frequently investigated common factors associated with 
psychotherapy outcome (Horvath, Del Re, Flückiger, & Symonds, 2011; Karver, Handelsman, 
Fields, & Bickman, 2006; Shirk, Karver, & Brown, 2011). In a meta-analysis of 190 studies of 
adult patients with various psychiatric diagnoses, alliance correlated moderately with outcome at 
r = .28 (95% confidence interval .25 to .30) (Horvath et al., 2011). A meta-analysis of child and 
youth psychotherapy had similar findings, rw1 = .22 (95% confidence interval .16 to .28) (Shirk et 
al., 2011). Given the robust association between therapeutic alliance and outcome, researchers 
have concluded that alliance is a critical component of effective psychotherapies (Horvath et al., 
2011; Miller & Mizes, 2000; Shirk et al., 2011).   
Substantial debate surrounds the importance of therapeutic alliance in eating disorders 
(EDs). Although qualitative research has consistently indicated that individuals with EDs find 
their relationship with the therapist to be important to their well-being, recovery, and treatment 
satisfaction (e.g., Escobar-Koch, Mandlich, & Urzua, 2012), quantitative research on the 
relationship between the alliance and outcome in ED treatment has yielded mixed results. 
Multiple studies have shown that therapeutic alliance predicts outcome (e.g., Bourion-Bedes et 
al., 2013; Constantino, Arnow, Blasey, & Agras, 2005; Zeeck & Hartmann, 2005); yet, other 
studies have found little or no association (e.g., Waller, Evans, & Stringer, 2012; Zaitsoff, Doyle, 
Hoste, & Le Grange, 2008). Discrepant results across studies may be due to study-level 
differences in therapeutic approach, ED diagnosis, patient age, or drop-out.   
                                                          
1
 rw = weighted mean correlation 
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The importance of early alliance relative to that of early symptom change in ED 
treatment is also unclear. A number of studies have observed strong associations between 
symptom change and therapeutic alliance in the first few weeks of treatment (Brown, Mountford, 
& Waller, 2013b; Constantino et al., 2005), as well as early symptom change and later outcomes 
(Le Grange, Accurso, Lock, Agras, & Bryson, 2014; Raykos, Watson, Fursland, Byrne, & 
Nathan, 2013). Thus, it could be argued that the alliance is simply a by-product of early 
symptom change, and that alliance-outcome associations that do not account for the role of early 
symptom change may be spurious (DeRubeis, Brotman, & Gibbons, 2005). To the extent that a 
quality alliance may result from versus promote change, some have questioned whether alliance 
is overvalued, and whether its importance may vary by treatment type (Brown, Mountford, & 
Waller, 2013a).  
Possible Moderators of the Relation between Therapeutic Alliance and Outcome 
The strength of the relation between therapeutic alliance and outcome reported in prior 
studies may depend on a number of study-level characteristics, including therapy type, mean 
patient age, patient diagnosis, alliance rater, and dropout rate. 
Therapy type. Findings regarding differences in the relationship between alliance and 
treatment outcome for different types of therapy have been inconclusive. In the non-ED 
literature, a study investigating two treatments for borderline personality disorder indicated that 
alliance was more important for outcome in patients receiving behavioral (i.e., dialectical 
behavioral therapy) versus non-behavioral (i.e., community care by experts) treatment (Bedics, 
Atkins, Harned, & Linehan, 2015). Conversely, one meta-analysis found that alliance was 
relevant to the outcome of therapy only when that therapy was relatively unstructured (i.e., non-
behavioral) (Crits-Christoph et al., 1991); though other meta-analyses have not replicated this 
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distinction (Horvath et al., 2011). In EDs specifically, CBT researchers have questioned the 
relationship between alliance and outcome, with certain studies finding no relationship between 
alliance and outcome in CBT for anorexia nervosa (AN; e.g., Waller et al., 2012) and bulimia 
nervosa (BN; e.g., Raykos et al., 2013).   
Patient age. The development of therapeutic alliance may differ in younger versus older 
patients. Specifically, child and adolescent patients may have limited abstract reasoning skills 
(Bravender et al., 2007), minimize or deny symptoms, or feel pressure from caregivers to enter 
treatment involuntarily (Sperry, Roehrig, & Thompson, 2009). Thus some have argued that 
clinicians should pay extra attention to establishing a strong alliance relative to other goals early 
in youth treatment (Sperry et al., 2009). In line with these suggestions, in studies of child and 
adolescent therapy in general, Shirk et al. (2011) found a trend for stronger alliance-outcome 
associations among younger patients. In contrast, there is also reason to believe that alliance-
outcome associations might be less important to outcome in youth with EDs. For example, 
family-based treatment (FBT), which empowers parents to WDNHFKDUJHRIWKHLUFKLOG¶VHDWLQJ, 
emphasizes a strong alliance with caregivers early in treatment, which may alter the nature of the 
relationship between patient-rated alliance and outcome. In a meta-analysis of youth treatment 
studies for a variety of psychiatric disorders, the alliance-outcome association was weaker for 
family versus individual therapies (McLeod, 2011). While prior ED studies have separately 
focused on patients of different ages, none have examined patient age as a moderator of the 
association between alliance and outcome.  
Patient diagnosis. Clinicians have posited differences in the overall quality of the 
alliance based on ED diagnosis and have speculated that treatment resistance among patients 
with AN may hinder the development of a positive alliance (Strober, 2004). However, multiple 
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studies have shown alliance to be relatively strong among patients with AN (Sly, Morgan, 
Mountford, & Lacey, 2013; Waller, et al., 2012). In fact, Antoniou and Cooper¶V qualitative 
review of the relationship between alliance and outcome in EDs (2013) suggested that the 
alliance strongly predicted outcome for patients with AN, whereas findings for BN, binge eating 
disorder (BED), and subthreshold eating disorders were mixed.  
Therapeutic alliance rater. Studies have shown differential effects depending on whether 
therapeutic alliance was rated by the patient, the therapist, or an independent observer. In some 
studies, patient and independent observer ratings of alliance have shown stronger relationships to 
treatment outcome than therapist ratings (Bachelor & Horvath, 1999). In the case of FBT for 
EDs, the alliance rating is also complicated by the presence of not only the patient but also the 
parents, who are expected to implement important treatment interventions. Differences between 
mother-rated, father-rated, and observer-rated alliance and outcome were noted in a study of 
FBT for AN (Ellison et al., 2012), with mother-rated alliance showing the strongest relationship 
to weight gain. Two different studies analyzing data from a large randomized controlled trial 
comparing CBT and IPT for BN (Constantino et al., 2005; Loeb et al., 2005) found that patient-
rated alliance predicted outcome, whereas observer-rated alliance did not. 
Drop-out. Drop-out is a substantial problem in ED treatment studies, with attrition rates 
ranging from 20-73% in inpatient and outpatient settings (Fassino, Pierò, Tomba, & Abbate-
Daga, 2009). ED research reflects consistent findings from the wider alliance literature, 
observing that poor alliance predicts drop-out (Morlino et al., 2007; Sly et al., 2014). Given that 
variability in therapeutic alliance is associated with drop-out, it is possible that studies with high 
drop-out would show different alliance-outcome associations versus those with low drop-out. 
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Other variables. Other variables, including how therapeutic alliance is measured, and 
how treatment outcome is defined, could also impact the relation between alliance and outcome.  
The Current Meta-Analysis 
Primary Questions. To better understand the relationship between therapeutic alliance 
and treatment outcome in EDs, we conducted the first meta-analysis on this topic. Specifically, 
we evaluated the aggregated strength of the relationship between alliance and outcome by 
conducting temporal analyses of symptom change. Thus change in ED symptoms (i.e., weight, 
ED behaviors, and ED cognitions) over the course of treatment was our definition of outcome in 
the current meta-analysis. A significant correlation between therapeutic alliance measured at 
some point in treatment and a treatment outcome, with no covariates in the model, does not 
demonstrate that the alliance is a causal mechanism of symptom change. In this scenario, there is 
no control over (1) temporal precedence (i.e., that alliance promotes change measured after 
alliance measurement) and (2) the potential role of change occurring prior to alliance 
measurement (i.e., the notion that the alliance may be epiphenomenal to symptom reduction that 
has already occurred). To better assess whether alliance changes independently from, or in 
interaction with, symptom change, we needed to analyze the alliance-outcome association across 
multiple points in treatment (with time lags to address temporal sequencing) and account for the 
role of prior symptom change (Brown et al., 2013a). Because the data required to perform 
temporal analyses were not included in published articles, our team contacted the corresponding 
authors of all studies meeting inclusion criteria to acquire the necessary data. Studies whose 
author(s) responded to our request and were able to retrieve the needed data were included in our 
meta-analysis (see Method).  
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Our analyses addressed four questions. The first three concerned the relationship between 
symptom change and later therapeutic alliance at different points in the treatment, and the fourth 
addressed the relationship between early alliance and later symptom improvement: (1) Does 
early change in symptoms (i.e., early improvement) predict early/mid alliance? (2) Does mid-to-
end of treatment change in symptoms predict alliance at the end of treatment? (3) Does change in 
symptoms across the entirety of treatment predict alliance at the end of treatment? (4a) Does 
early/mid alliance predict subsequent change in symptoms? And (4b) Do early/mid alliance and 
early symptom change each predict unique variance in subsequent change in symptoms (i.e., 
question 4b is an extension of question 4a, but controlling for symptom change)? 
 Potential moderators. In addition to evaluating the strength of the relationship between 
therapeutic alliance and symptom change, we explored potential moderators (i.e., study-level 
characteristics that could explain variance in effect sizes). Based on prior literature, we 
hypothesized that study-level characteristics including therapy type, patient age, patient 
diagnosis, alliance rater, and study drop-out rate would contribute to differences in effect size.  
Method 
Inclusion Criteria 
We set the following inclusion criteria for studies in our meta-analysis: (a) comprised a 
sample of patients diagnosed with one or more ED(s), including AN, BN, BED, EDNOS, or sub-
threshold diagnoses; (b) included a measure of therapeutic alliance at one or more time points to 
one or more sample groups during the study (e.g., Working Alliance Inventory, Helping Alliance 
Questionnaire, Helping Relationship Questionnaire, or California Psychotherapy Alliance 
Scales); (c) conducted and reported at least one statistical analysis of the relationship between 
alliance and a primary treatment outcome variable (e.g., weight, binge/purge frequency, self-
report or interview measure of ED psychopathology); (d) was not a case report; (e) was 
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published between the dates of January 1978 (i.e., the date of the first ED treatment study to 
report alliance-outcome data) and January 2014 (f) was published in English; and (g) did not 
utilize data already reported in another study included in the meta-analysis. All studies meeting 
each of these requirements were retained for further inspection, while the remaining studies were 
assigned reasons for exclusion. 
Selection of Studies 
To identify relevant studies, we conducted a computer-based search using PsycINFO, 
PubMed, and Academic Search Premier. We also searched ProQuest Dissertations and Theses 
specifically to locate unpublished studies. We identified search terms for alliance and EDs in the 
controlled vocabulary of each database. For example, in PsychINFO, the terms for therapeutic 
alliance were alliance, therapeutic alliance, treatment alliance, helping alliance, working 
alliance, psychotherapy relationship, therapeutic relationship, therapeutic bond, helping 
relationship, and patient therapist relationship. The PsychINFO terms for EDs were eating 
disorders, anorexia, bulimia, binge eating disorder, EDNOS, and eating disorder not otherwise 
specified. We then searched each database for studies that were tagged with both alliance and 
EDs controlled-vocabulary terms. Lastly, we mined the reference section of eight review articles 
relevant to alliance in EDs which we identified via the initial electronic database search (Fassino 
& Abbate-Daga, 2013; Manlick, Cochran, & Koon, 2013; Martin et al., 2011; Shirk et al., 2011; 
Vitousek & Watson, 1998; Vocks et al., 2010; Westwood & Kendal, 2012; Wilson, 2011) for 
any additional relevant studies that may have been missed.  
The electronic database search combined with the hand search of the review articles 
resulted in an initial candidate study pool of 767 studies. These studies were then reduced in a 
stepwise fashion by two independent coders (the first and second authors), as described in the 
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PRISMA diagram (Figure 1). The two coders first screened each abstract, applying the a priori 
inclusion and exclusion criteria. Of the initial pool of abstracts, 48 studies were retained for full-
text screening. The inter-rater reliability between the two coders for abstract screening was 
acceptable with a kappa = .67, p < .01. When the coders¶ ratings diverged, they were discussed 
until consensus was achieved. The two coders then independently screened the full text of the 48 
retained studies. This process resulted in a reduced pool of 27 eligible studies. The inter-rater 
reliability between the two coders for the full-text screening was substantial with a kappa = .76, p 
<.01. These studies were then back-searched using Google Scholar in order to locate any 
additional studies referencing those already included in the pool. None of the new studies located 
during this final step met inclusion criteria.  
Requests for Additional Data 
In order to perform the temporal analyses necessitated by our research questions, our 
team contacted the corresponding authors of all 27 eligible studies to request additional²
typically unpublished²data that would be required. We formulated individualized email 
requests for each author(s) based on data available from the published report. We received data 
from the participating studies between May and October of 2014.  
Of the 27 authors who received email requests, 20 responded positively, and were able to 
forward all necessary data in a usable format for the proposed temporal analyses. Only six 
authors responded negatively to our request, citing that they either (1) did not wish to participate 
(Ellison et al., 2012; Hildebrandt, Loeb, Troupe, & Delinsky, 2012; Hoffman, 2006); (2) were 
not able to provide the requested data because it was inaccessible (Treasure et al., 1999; Wilson 
et al., 1999); or (3) did not collect data from the needed time points (Hartmann, Orlinsky, Weber, 
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Sandholz, & Zeeck, 2010). Finally, one dissertation (Leonard, 2007) could not be included 
because we could not locate contact information for the corresponding author.  
Measures of Outcome (i.e., ED Symptoms) and Therapeutic Alliance 
Outcome (i.e., ED symptoms). In the 20 studies included in our meta-analysis, 
investigators measured improvement in ED symptoms with several relevant measures including 
body mass index (BMI), weight, percent ideal body weight, binge/purge frequency, vomiting 
frequency, body checking frequency, Eating Disorder Examination-Questionnaire (EDE-Q), 
Outcome Questionnaire-45.2, and urge to restrict. 
Therapeutic alliance. In the 20 studies included in our meta-analysis, investigators 
measured therapeutic alliance with nine different scales: Agnew Relationship Measure; Bern 
Post-Session Reports for Patients; California Psychotherapy Alliance Scales; Helping Alliance 
Questionnaire; Helping Relationship Questionnaire; System for Observing Family Alliances; 
Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy; 
Treatment Satisfaction Scale; and Working Alliance Inventory. We broadly defined early 
alliance as the point in treatment when alliance was first measured. For most studies, this point in 
treatment was between sessions 1 and 5 with the exception of one naturalistic longitudinal study 
that first measured the alliance at 6 months of treatment, which was approximately mid-way 
through therapy (average length of treatment, M = 18 ± 19 months; Paulson Karlsson, Clinton, & 
Nevonen, 2013). We defined mid alliance as the point at which the alliance rating occurring 
closest to the midpoint of treatment. For most studies, mid alliance was measured between 
session 6 and 12. We defined late alliance as the alliance rating at the end of treatment. This was 
always the last alliance measurement taken; timing varied across studies. 
Levels of Each Moderator Variable 
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 We examined the following variables as possible moderators of the alliance-outcome 
effect size, classifying each study as falling into one of the following levels on each moderator. 
 Therapy type. We coded therapy type as a categorical variable with five categories: 
behavioral weight-loss therapy (BWLT), CBT, FBT, individual-focused therapy, or multiple 
therapies. The BWLT category comprised a manualized behavioral treatment following the 
tetrahydrolipstatin-based weight loss manual that focuses on balanced nutrition and physical 
activity to promote weight loss (Margraf, 2000; Munsch, Biedert, & Keller, 2003). The CBT 
category included manualized treatments that employ both cognitive and behavioral strategies to 
promote eating-disorder symptom change. The FBT category included a manualized treatment 
that empowers SDUHQWVWRHIIHFWFKDQJHLQWKHLUFKLOG¶VHDWLQJ-disorder symptoms (Lock, Le 
Grange, Agras, & Dare, 2001). The individual-focused therapy category included therapies that 
fostered the development of insight in related areas, but did directly encourage change in eating-
disorder symptoms, including adolescent-focused therapy (AFT), IPT, and supportive 
psychotherapy (SPT). The multiple therapies category included studies in which participants 
received two or more different types/modes of therapy either simultaneously or consecutively 
(e.g., a mixture of inpatient, day-patient, outpatient, individual, group, and/or family therapies 
[Paulson Karlsson et al., 2013], a treatment combining individual therapy and a supportive 
program aimed at improving weight and eating behaviors [Bourion-Bedes et al., 2013]).  
Mean age. We recorded the mean age of each study sample as a continuous variable. 
When there was more than one sample in a study (e.g., a randomized controlled trial), we 
recorded the mean age for each sub-sample. However, when the mean age for each subsample 
was not reported and there was no statistically significant difference in mean age between the 
sub-samples, the mean age for the total sample was used for both subsamples.   
META-ANALYSIS OF THE RELATION BETWEEN THERAPEUTIC ALLIANCE                                                      
 
15
  ED diagnosis. We coded ED diagnosis as a categorical variable with four categories: 
AN, BN, BED, or multiple. A sample was coded as multiple when the sample was composed of 
people with different ED diagnoses.  
 Therapeutic alliance rater. We coded therapeutic alliance rater as a categorical variable 
with two categories: patient-rated or independent observer-rated. In instances where data from 
more than one rater of the alliance was included in a study (e.g., patient-rated and parent-rated 
alliance or patient-rated and therapist-rated alliance), we chose to use the patient-rated alliance or 
the independent observer-rated alliance (if patient-ratings were not provided) because patient 
ratings and independent observer ratings have shown stronger associations to treatment outcome 
than parent or therapist ratings of the alliance (Bachelor & Horvath, 1999; Horvath et al., 2011). 
We did not have any studies in our pool that only collected therapist- or parent-rated alliance 
data.  
 Study drop-out rate. We recorded study drop-out rate as a continuous variable. When 
there was more than one sample in a study (e.g., a randomized controlled trial), each sub-sample 
was assigned the same study drop-out rate, unless drop-out was reported individually for each 
sub-sample.   
Effect Size Information 
We used the standardized regression coefficient (ȕ) to evaluate effect size for each of our 
four meta-analytic research questions. Rather than extracting effect-size data from the original 
papers, we obtained more detailed information (i.e., descriptive statistics and correlations) 
directly from the authors of each study²this was necessary because many studies did not report 
the information needed to calculate temporal effect sizes. When there was missing data in the 
summary statistics, we used pairwise deletion in the analyses required to obtain the effect sizes 
of interest to increase sample size and thus power. When there was no missing data reported in 
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the summary statistics, analyses required to obtain the effect sizes of interest were based on the 
total sample. 
To facilitate comparison across therapy types within each study, we calculated separate 
effect sizes of the alliance-outcome relation for each treatment arm. We then calculated our own 
effect sizes, standard errors (SE), 95% confidence intervals (CI), and p-values using individual 
multiple linear regression analyses in SPSS. In all analyses, we coded treatment outcome 
variables such that higher positive scores indicated greater symptom change (e.g., increased BMI 
in AN trials, decreased binge/purge frequency in BN trials) and stronger alliance. Some studies 
utilized multiple measures of the same construct²either alliance or ED symptoms. When a 
particular measure included more than one subscale that could be combined into a global score 
(e.g., EDE-Q), we used the global score to calculate the effect size for the relation between 
alliance and outcome. When a measure contained subscales that could not be combined to 
achieve a total score (e.g., Working Alliance Inventory), we averaged the effect sizes for the 
outcome-alliance relation for each subscale, to obtain an average effect size for that study (as in 
Thomas, Vartanian, & Brownell, 2009).  
For the first question (i.e., Does early symptom change predict early/middle alliance?), 
the regression analysis included (1) ED symptoms at baseline, and (2) change in symptoms from 
baseline to when alliance was first measured, as predictors of the first measure of alliance. Thus, 
the standardized regression coefficient indexed the relationship between early symptom change 
and alliance, controlling for baseline symptom level. For the second question (i.e., Does middle 
to end of treatment symptom change predict later alliance?), the regression analysis included (1) 
ED symptoms when alliance was first measured and (2) change in symptoms from when alliance 
was first measured to the end of treatment as predictors of alliance at the end of treatment. 
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Therefore, the standardized regression coefficient indexed the relationship between change in 
treatment outcome and alliance at the end of treatment, controlling for symptom level at the time 
of first alliance measurement. For the third question (i.e., Does symptom change across treatment 
predict later alliance?), the regression analysis included (1) ED symptoms at baseline and (2) 
change in symptoms from baseline to end of treatment as predictors of alliance at the end of 
treatment. Thus, the standardized regression coefficient indexed the relationship between change 
in treatment outcome from baseline to end of treatment and alliance at the end of treatment, 
controlling for baseline symptom level. For the fourth question (i.e., Does early/mid alliance 
predict subsequent symptom change?), the regression analysis included (1) alliance and (2) ED 
symptoms when the alliance was first measured as predictors of change in treatment outcome 
from when the alliance was first measured to the end of treatment. Therefore, the standardized 
regression coefficient indexed the relationship between early/mid alliance and subsequent 
symptom change, controlling for symptom level at the time of alliance measurement. We also 
conducted a second regression analysis to examine whether early/mid alliance predicts 
subsequent symptom change above and beyond early symptom change. Thus, the regression 
analysis included (1) the first measure of alliance and (2) change in symptoms from baseline to 
when alliance was first measured as predictors of change in treatment outcome from when the 
alliance was first measured to the end of treatment. The standardized regression coefficient 
indexed the relationship between early/mid alliance and subsequent symptom change while 
statistically controlling for early symptom change.   
Meta-analytic Procedures 
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For each research question, we pooled relevant effect sizes, weighted by their inverse-
variance (1/SE2). The SE of each effect size (ȕ) was calculated using the formula provided by 
Cohen, Cohen, West, & Aiken (2003; also see Card, 2013): 
ܵܧఉ೔ ൌ ඨ  ?Ȃ ௒ܴଶ݊ െ ݇ െ  ?ඨ  ? ? െ  ௜ܴଶ 
where ܴ௒ଶis the variance explained in the dependent variable by the independent variables in the 
regression model, ܴ௜ଶis the variance explained in the independent variable of interest by the 
remaining independent variables in the regression model, n is the sample size, and k is the 
number of independent variables in the regression model. We interpreted the magnitude of each 
effect size according to &RKHQ¶V (1988) conventions for correlation coefficients, where .10 is 
small, .30 is moderate, and .50 is large.  
To allow us to generalize our results beyond the current sample, we used a random-
effects model. We assessed pXEOLFDWLRQELDVXVLQJ(JJHU¶VWHVW(JJHU Davey, Schneider, & 
Minder, 1997), which examines the presence of asymmetry in a funnel plot of effect sizes. For 
each research question, we also assessed whether the effect sizes were more heterogeneous than 
expected by sampling variability alone using the test of heterogeneity (Q-statistic). When there 
was evidence of heterogeneity, we used the I2 statistic to quantify the extent of heterogeneity. 
We then conducted follow-up moderator analyses using random-effects analogue to ANOVA for 
categorical moderators, and random-effects meta-regression for continuous moderators. When 
one or more statistically significant moderators were at least moderately correlated, we 
conducted a meta-regression analysis in which we controlled for their shared association. We 
conducted all analyses using Comprehensive Meta-Analysis Version 2.0 software program 
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(Borenstein, Hedges, Higgins, & Rothstein, 2005) except for the meta-regressions which we 
conducted using SPSS macros (Lipsey & Wilson, 2001). 
Results 
(1) Does early symptom change predict early/mid alliance? 
 Omnibus test. A total of 18 independent effect sizes from 14 different reports evaluated 
the relationship between early symptom change and early/mid therapeutic alliance (Table 1). For 
most reports, early/mid alliance was measured between sessions 3 and 10 of treatment; one 
naturalistic longitudinal study first measured the alliance after 6 months of treatment, which was 
approximately mid-way through therapy in this particular design (average length of treatment, M 
= 18 ± 19 months) (Paulson Karlsson et al., 2013). As expected, greater positive change in 
symptoms (i.e., greater improvement) from baseline to when the alliance was first measured 
predicted stronger early/mid alliance, ȕ = .19, 95% CI [.11, .28], z = 4.38, p < .0001. The 
magnitude of the mean effect size was small-to-moderate and there was no evidence of 
SXEOLFDWLRQELDV(JJHU¶VUHJUHVVLRQLQWHUFHSW t (16) = .06, p = .95. 
Moderator analyses. In addition, the effect sizes were heterogeneous, Q (17) = 28.41 p = 
.04, but the extent of heterogeneity was low, I2 = 40.16. In follow-up moderator analyses, study 
drop-out rate was associated with effect sizes at trend-level, Q
 
(1) 3.65, p = .06. Specifically, 
studies with higher drop-out rates had larger effect sizes, slope = .01, 95% CI [-.0002, .014], z = 
1.91, p = .06. To further evaluate this finding, we examined the mean effect size at high (+1 SD) 
and low (-1 SD) levels of study drop-out rate (weighted M = 14.60% drop-out rate, SD = 5.19). 
At 1 SD above the mean of study drop-out rate, the effect size was small-to-moderate and 
statistically significant, ȕ = .21, 95% CI [.13, .30], z = 4.91, p < .001. Likewise, at 1 SD below 
the mean of study drop-out rate, the effect size was small and statistically significant, ȕ = .14, 
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95% CI [.04, .24], z = 2.84, p = .004. Taken together, these findings indicate a positive linear 
relationship between the magnitude of the effect sizes and study drop-out rate. None of the 
remaining moderators were statistically significant (Table 2). 
(2) Does mid-to-end of treatment change in symptoms predict later alliance? 
Omnibus test. A total of ten independent effect sizes from eight different reports 
evaluated the relationship between mid-to-end of treatment symptom change and later 
therapeutic alliance (see Table 3). Alliance in all reports was measured at the end of treatment 
(i.e., at the final treatment session). Results for the overall mean effect size indicated that change 
in symptoms (i.e., improvement) from when early/mid alliance was measured until the end of 
treatment was not related to later alliance, ȕ= .10, 95% CI [-.04, .24], z = 1.46, p =  .15. The 
mean effect size was not statistically significant and there was no evidence of publication bias, 
(JJHU¶VUHJUHVVLRQLQWHUFHSW .02, t (8) = .02, p = .97.  
Moderator analyses. Because the effect sizes were homogenous, Q (9) = 2.79, p = .97, 
we did not evaluate potential moderators.2  
(3) Does change in symptoms across treatment predict later alliance?  
 Omnibus test. A total of 18 independent effect sizes from 12 different reports evaluated 
the relationship between change in symptoms across treatment and later alliance (Table 4). In 
almost all reports, later alliance was measured at the end of treatment. As expected, greater 
SRVLWLYHFKDQJHLQV\PSWRPVLHLPSURYHPHQWDFURVVHDFKVWXG\¶VGXUDWLRQSUHGLFWHGgreater 
subsequent alliance, ȕ = .17, 95% CI [.06, .29], z = 2.96, p = .003. The mean effect size was 
                                                          
2
 Although moderator analyses are often underpowered in meta-analyses comprising a relatively small 
number of studies, we chose to remain conservative by following the recommendations of Cooper, 
Hedges, & Valentine (2009) and Lipsey and Wilson (2001) not to evaluate moderators following a non-
significant omnibus test. 
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small-to-moderate and there was no evidence of publication bias, (JJHU¶s regression intercept = 
.81, t (16) = .94, p = .36.  
Moderator analyses. Effect sizes were homogenous, Q (17) = 24.17, p = .12, so we did 
not evaluate moderators.  
(4a) Does early/mid alliance predict subsequent symptom change? 
Omnibus test. A total of 19 independent effect sizes from 15 different reports evaluated 
the relationship between early/mid therapeutic alliance and change in symptoms from when 
early/mid alliance was measured to the last time-point of data on symptoms available in each 
report (see Table 5). For almost all reports, the last time-point of data on symptoms was the end 
of treatment; in one naturalistic longitudinal study, alliance was assessed after 6 months of 
treatment3 (Paulson Karlsson et al., 2013). As expected, greater early/mid alliance predicted 
greater subsequent symptom change, ȕ = .13, 95% CI [.05, .22], z = 3.10, p = .002. The 
magnitude of the mean effect size was small and there was no evidence of publication bias, 
(JJHU¶VUHJUHVVLRQLQWHUFHSW t (17) = .67, p = .51.  
Moderator analyses. The effect sizes were heterogeneous, Q (18) = 26.55, p = .09, and 
the extent of heterogeneity was low, I2 = 32.20. As such, we evaluated potential moderators. 
Therapy type was related to effect size, Q (4) = 10.61, p = .03. Specifically, greater early/mid 
alliance predicted greater subsequent positive change in treatment outcome for studies involving 
multiple therapies (ȕ = .18, 95% CI [.05 .32], z = 2.70, p = .007, k = 6); individual-focused 
therapies (ȕ = .21, 95% CI [.05, .37], z = 2.56, p = .01 k = 4); and FBT (ȕ = .31, 95% CI [.08, 
.54], z = 2.62, p = .009, k = 3). In contrast, early/mid alliance was not related to subsequent 
                                                          
3
 While Paulson Karlsson et al. (2013) also measured alliance 36 months after the start of treatment, we 
did not include those data in the current meta-analysis because the length of follow-up at the final time 
point of this longitudinal study differed so greatly from the other included studies, which were primarily 
much briefer randomized controlled trials. 
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positive change in treatment outcome for studies involving BWLT (ȕ = -.05, 95% CI [-.20, .11], 
z = -.59, p = .56, k = 2), and CBT (ȕ = -.02, 95% CI [-.25, .21], z = -.19, p = .85, k = 4). A 
follow-up meta-regression analysis evaluated mean differences in effect sizes as a function of 
therapy type. In the meta-regression, we used CBT as the reference group for therapy type 
(BWLT was not suitable to serve as the reference group because there were only two studies). 
Therapy type accounted for 43% of the variance in the effect sizes, R2 = .43, Q (4) = 10.35, p = 
.04. The mean effect size for studies involving FBT were larger than the mean effect size for 
studies involving CBT, B = .31, z = 2.12, p = .03. Likewise, there was a non-statistically 
significant trend indicating that the mean effect for studies involving multiple therapies tended to 
be larger than the mean effect size for studies involving CBT, B = .18, z = 1.78, p = .07. 
Similarly, there was also a non-statistically significant trend indicating that the mean effect size 
for studies involving individual-focused therapies tended to be larger than the mean effect size 
for studies involving CBT, B = .21, z = 1.76, p = .07. Also, the mean effect size for studies 
involving BWLT did not differ from the mean effect size for studies involving CBT, B = -.04, z 
= -.37, p = .71, although in this case the size and direction of the effect did not reflect a similar 
pattern to the other variables, i.e., it was more similar to the results for CBT. In sum, greater 
early/mid alliance predicted greater subsequent positive change in treatment outcome for studies 
involving FBT, multiple therapies, and individual-focused therapies relative to studies involving 
CBT where there was no such effect. None of the remaining moderators were related to 
variability in the effect sizes (Table 2). 
(4b) Does early/mid alliance predict subsequent symptom change above and beyond early 
symptom change? 
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Omnibus test. A total of 15 independent effect sizes from 11 different reports allowed us 
to evaluate the relationship between early/mid therapeutic alliance and change in symptoms from 
when early/mid alliance was measured to the last time-point of data on symptoms available in 
each report while statistically controlling for early symptom change (Table 6). For almost all 
reports, the last time-point of data on symptoms was at end of treatment; however, for one study, 
the last time-point of data on symptoms was at 6-month follow-up (Paulson Karlsson et al., 
2013). The mean effect size was not statistically significant, ȕ = .07, 95% CI [-.04, .17], z = 1.26, 
p = .21, and there was no evidence of publication bias, EgJHU¶VUHJUHVVLRQLQWHUFHSW , t (13) 
= .09, p = .93.  
Moderator analyses. The effect sizes were heterogeneous, Q (14) = 23.15, p = .058, and 
the extent of heterogeneity was low, I2 = 39.52%. Thus, we evaluated potential moderators. 
Sample mean age was related to effect size, Q (1) = 16.20, p < .01. Specifically, studies with 
older samples had smaller effect sizes relative to studies with younger samples, B = 03, z = -4.03, 
p < .001. To further evaluate this finding, we examined the mean effect size at high (+1 SD) and 
low (-1 SD) levels of sample mean age (weighted M = 22.08 years old, SD = 5.94). At 1 SD 
above sample mean age, the effect size was small and was not statistically significant, ȕ = -.10, 
95% CI [-.20, .01], z = -1.71, p = .09. This finding indicates that early/mid alliance did not 
predict change in symptoms from when the early/mid alliance was measured to the end of 
treatment above and beyond early symptom change in studies with older patients. However, at 1 
SD below the sample mean age, early/mid alliance predicted greater improvement in symptoms 
from when the early/mid alliance was measured to the end of treatment above and beyond early 
symptom change in studies with younger patients, ȕ = .22, 95% CI [.11, .33], z = 3.98, p = .0001. 
The magnitude of the effect size was small-to-moderate.  
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ED diagnosis was also related to the effect sizes, Q (2) = 6.10, p = .04. Specifically, the 
mean effect size was statistically significant and small for studies with samples of AN (ȕ= .16, 
95% CI [.04, .27], z = 2.57, p = .01), but was not significant for studies with samples of BN (ȕ = 
-.10, 95% CI [-.26, .06], z = -1.17, p = .24) and studies with mixed ED samples (ȕ= .06, 95% CI 
[-.18, .30], z = .49, p = .62). In short, early/mid alliance predicted greater improvement in 
symptoms from when the early/mid alliance was measured to the end of treatment above and 
beyond early symptom change in studies with samples of AN. None of the remaining moderators 
were statistically significant (Table 2). 
Sample mean age (R2 = .53, p =  .04) and ED diagnosis &UDPHU¶V9 , p < .001) were 
both moderately associated with therapy type. However, sample mean age and ED diagnosis 
were not related (R2 = .14, p =  .33). Thus, we conducted a follow-up meta-regression to examine 
whether sample mean age and ED diagnosis remained statistically significant predictors of effect 
size while controlling for shared variance with therapy type. In the meta-regression, we used AN 
as the reference group for ED diagnosis and individual-focused therapies as the reference group 
for therapy type. Mean age, ED diagnosis, and therapy type together accounted for 88% of the 
variance in the effect sizes, R2 = .88, Q (6) = 20.42, p = .002. Sample mean age accounted for 
unique variance in the effect sizes above and beyond ED diagnosis and therapy type, B = -.03, z 
= -3. 01, p = .003. In contrast, differences in ED diagnosis did not account for unique variance in 
the effect sizes above and beyond mean age and therapy type. Differences in therapy type did not 
account for variance in the effect sizes. In sum, findings indicated that early/mid alliance 
predicted greater subsequent improvement in symptoms above and beyond early symptom 
change in studies with younger patients, regardless of their ED diagnosis and therapy type. 
Discussion 
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Although ED clinicians have long stressed the role of therapeutic alliance in facilitating 
symptom change, ED researchers studying behavioral treatments have instead stressed the 
importance of early symptom change for promoting therapeutic alliance and have debated the 
relative and temporal influences of these two factors on each other and outcome. Our meta-
analysis of 20 ED treatment studies, examining the relations between symptom change and 
alliance across time and samples, supports a reciprocal relationship between symptom change 
and alliance. In addition, our analyses are unique in that they are the first in ED treatments to 
identify that the relative importance of therapeutic alliance for treatment outcome may differ 
across treatment type, patient age, and patient diagnosis. Interestingly, alliance rater 
(independent rater versus patient) did not impact effect sizes. Further, the current study 
succeeded in connecting multiple well-known research groups in the field of EDs from across the 
globe, representing data from nine different countries.  We evaluated four distinct research 
questions, finding statistically significant results for three of the four, with all effect sizes being 
in the hypothesized direction.  
We identified the strongest association between symptom change and subsequent 
alliance, specifically a small-to-moderate sized relationship between early symptom change and 
early/mid alliance (question 1), as well as a small-to-moderate relationship across-treatment 
symptom change and subsequent alliance (question 3). This relationship between symptom 
change and alliance early in therapy was not moderated by treatment type, ED diagnosis, or other 
factors, and therefore should be assumed to hold across all levels of these moderator variables. 
The finding that positive symptom change strengthens therapeutic alliance is consistent with 
evidence from other psychological disorders, including depression (Tang & DeRubeis, 1999).   
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However, additional analyses also supported the temporal role of the early alliance in 
facilitating later symptom change. Results for question 4a (Does early/mid alliance predict 
subsequent symptom change?) indicated that early/mid alliance ratings also predicted subsequent 
changes in outcome. Although differences were noted in the relationship between early alliance 
and later symptom change between different types of treatment, these results were only 
significant at the trend level, and should therefore be interpreted with caution. The results of 
moderator analyses supported the role of early alliance in predicting later symptom-change for 
individual-focused therapies (e.g., IPT, AFT, and SPT), FBT, and multiple therapies; but not for 
CBT or BWLT. Further, meta-regression to explore individual comparisons indicated that the 
differences between CBT and other treatments, excepting BWLT, were particularly strong. 
These results are very interesting in light of the importance of early symptom change to outcome 
in CBT (Brown et al., 2013b). It is possible that the alliance is particularly critical in therapies 
where it is viewed and cultivated as an agent of change; however, further research is needed to 
confirm this.  
 Unique analyses compared the relative strength of the associations between treatment 
outcome and (a) early therapeutic alliance, and (b) early symptom change, including moderator 
analyses to explore potential differences according to patient age and patient diagnosis. The 
results indicated that the early alliance was significantly related to subsequent symptom change 
for younger patients and for patients with AN, but not for older patients or those with other ED 
diagnoses. Further analyses controlling for the correlations between patient age, ED diagnosis, 
and treatment type, found that patient age produced the only statistically significant effect after 
controlling for ED diagnosis and therapy type, indicating that it was a particularly important 
predictor of a stronger association between the early alliance and outcome. These findings reflect 
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the observations of some alliance researchers outside the field of EDs (Shirk et al., 2011), as well 
as clinicians who treat adolescents. Importantly, age was a significant moderator even after 
controlling for treatment type (i.e., individual versus family-based), suggesting that extra 
attention may need to be paid to the alliance relative to other goals early in treatment for younger 
patients with EDs (Sperry et al., 2009), regardless of theoretical orientation. Of course, given that 
age was examined as a study-level (rather than individual-level) moderator in this meta-analysis, 
we can only draw conclusions about studies that recruited younger patients, rather than any 
specific youth patient, or youth patients in general.  
Our findings also suggested that drop-out rate should be considered when interpreting the 
size and significance of the relation between symptom change and early alliance ratings. Results 
indicated that when drop-out was low, symptom change showed a smaller relationship to 
early/mid alliance ratings, whereas when it was high, early improvement more strongly predicted 
early/mid alliance ratings. Patients drop out of studies for a wide range of reasons and at various 
points in treatment (both early and late). Studies that retain patients who are otherwise likely to 
drop out may include patients with a variety of factors influencing both alliance and symptom 
change, introducing other sources of variance and error into the symptom change/alliance 
relationship. It is also possible that patients who drop out of treatment tend to have lower levels 
of the alliance at the outset or are initially less symptomatic. Thus, it could be argued that drop-
out, outcome, and therapeutic alliance are confounded. This possibility should temper the 
interpretation that early symptom change predicts later alliance as well. A more nuanced study of 
the drop-out/alliance/outcome relationships in ED samples would help to clarify these questions. 
Within the 20 studies included in this meta-analysis, nine different measures of 
therapeutic alliance were used. Due to the diverse range of alliance measures, it was not possible 
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to include this variable in our moderator analyses. Research indicates that the shared variance 
among the numerous measures of therapeutic alliance is less than 50%, even among the four so-
FDOOHG³FRUH´PHDVXUHVLH:RUNLQJ$OOLDQFH,QYHQWRU\+HOSLQJ$OOLDQFH4XHVWLRQQDLUH
California Psychotherapy Alliance Scale, and Vanderbilt Psychotherapy Process Scale) 
(Horvath, 2009). This suggests that these scales may all be measuring slightly different 
constructs. Future research should be designed to investigate if and how the type of alliance 
rating measure used may affect the resulting alliance-outcome associations.  
 This study has limitations that should be noted. First, our sample of included studies was 
relatively small. Although there has been an increased focus on therapeutic alliance in recent 
years, there are still relatively few treatment studies within the ED field that have collected both 
alliance and outcome data. Moreover, of the studies that have collected such data, most only 
assess these variables a few times across treatment. In order to truly begin to untangle this issue, 
alliance and outcomes should be measured repeatedly, from session 1 to end of treatment. Our 
findings, combined with others from the ED field (i.e., Tasca & Lampard, 2012), suggest that 
alliance and outcomes are not static constructs. They change over time and it is quite possible 
that it is the change in these constructs that is key.  Moreover, although our meta-analysis 
provided the unique opportunity to evaluate changes in both alliance and symptoms over time, 
the temporal precedence of one over the other does not necessarily imply causality.  
 Further, despite our best attempts to locate all relevant studies and contact all 
corresponding authors, there remained a number of applicable studies that were excluded from 
our meta-analyses because of (1) difficulties contacting the corresponding author(s), or (2) the 
inability of corresponding author(s) to retrieve the needed data. The inclusion of these missing 
data could have yielded different results. Second, with regard to our moderator analyses, it is 
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important to note that study sample sizes (k) for many of these analyses were quite small, and 
therefore, results from these analyses should be interpreted with caution. This is particularly true 
of the moderator analyses involving therapy type. Third, the majority of the included studies 
were composed of Caucasian females (~90%), which greatly reduces the generalizability of our 
results to only one subset of the population receiving ED treatment. It is not yet known whether 
these results would apply to males and/or patients from ethnically diverse backgrounds. In fact, 
one meta-analysis investigating the moderating effects of the presence of racial/ethnic minorities 
on the strength of the alliance-outcome association, found that the percentage of overall 
minorities (particularly African Americans) attenuated the alliance-outcome association 
(Flückiger et al., 2013). Unfortunately, due to largely homogenous study samples in terms of 
race and gender and a lack of data regarding patient comorbidities (e.g., substance use disorders), 
we were unable to investigate the moderating impact of these variables. Fourth, other patient 
variables (e.g., personality characteristics, attachment style) and therapist characteristics (e.g., 
gender, experience level) that may impact both alliance and outcome were not measured in a 
sufficient number of studies to be included as potential moderators. A final limitation of the 
current meta-analysis is that it was impossible to exclude all third-variable confounds. For 
instance, it is plausible that patient characteristics not accounted for in our analyses, such as high 
interpersonal functioning, patient level of insight, or patient motivation or expectancies for 
change, are associated with both greater alliance and outcome (Jones, Lindekilde, Lübeck, & 
Clausen, 2015).  
Conclusions 
 Overall, the bidirectional relationship between therapeutic alliance and outcome found in 
our meta-analysis strongly suggests the critical value of both early and sustained symptom 
change, as well as the patient-therapist relationship in this clinically challenging population. 
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Symptom improvement was shown to predict subsequent alliance both early in and across the 
span of treatment, irrespective of treatment type, patient age, or ED diagnosis. Differences in the 
strength of the relationship between the early alliance and treatment outcome were observed for 
different treatments, with CBT and BWLT showing weaker associations than other treatment 
types. Multivariate analyses examining the relative strength of associations between early 
alliance and later outcome controlling for early symptom change, and examining differences in 
these relationships according to patient age and patient diagnosis, found that early symptom 
change accounts for a moderate portion of observed associations between the early alliance and 
outcome. Analyses indicated that for older patients and those with BN, BED, and 
mixed/subclinical diagnoses, attention to early symptom change may yield the most benefit for 
both the early alliance and eventual treatment outcome. However, results of these analyses 
indicated that younger patients may show specific benefit from additional attention to the early 
alliance, which showed associations with outcome even when early symptom change was taken 
into account. These results support a more fine-grained and complex approach to research 
concerning the inter-relationships between symptom improvement, alliance, and treatment 
outcome, with attention paid to possible differences in these relationships according to treatment 
approach and patient factors. Further research is needed to determine the extent to which the 
bidirectional relationship between therapeutic alliance and symptom change and its attendant 
moderators is unique to EDs, or more broadly applicable across psychiatric disorders.   
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Figure 2. Forest plots for all meta-analytic research questions.   
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Table 1. Question 1: Does early symptom change predict early/mid all? 
  Moderator variables  Effect size information 
Report N Mean 
age DX 
Therapy 
setting 
Therapy 
type/mode 
Alliance  
rater 
 
Session/ 
of Total 
Study 
drop-
out (%) 
Alliance 
rating 
measure 
ȕSE) 95% CI p 
Bourion-Bedes et al. (2013)(A) 66 15.30 AN Inpatient Multi/IND PA 3/VAR 0 HAQ -.01(.13)b -.26, .23 .92 
Bourion-Bedes et al. (2013)(B) 42 15.30 AN Outpatient Multi/IND PA 3/VAR 0 HAQ .19(.17)b -.15, .53 .28 
Brown et al. (2013) 35 25.70 AN Outpatient CBT/IND PA 6/30-40 32.31 WAI .46(.19)c .10, .83 .01 
Constantino et al. (2005)(A) 75 28.10 BN Outpatient CBT/IND PA 12/19 25.91 HAQ .54(.19)c .17, .90 < .01 
Constantino et al. (2005)(B) 82 28.10 BN Outpatient IPT/IND PA 12/19 25.91 HAQ .40(.12)c .16, .63 < .01 
Forsberg et al. (2013)(A) 40 14.80 AN Outpatient AFT/IND IO 3-5/32 17.36 WAI -.05(.17)b -.38, .29 .78 
Forsberg et al. (2013)(B) 38 14.00 AN Outpatient FBT/IND IO 3-5/20 17.36 WAI .35(.17)b .02, .67 .04 
Isserlin & Couturier (2012) 13 14.00 AN Outpatient FBT/IND IO 3/MDN=12 42.86 SOFTA .55(.39)  -.22, 1.32 .16 
Paulson Karlsson et al. (2013) 41 23.90 AN MIX Multi/MIX PA MO6/ MO18±19 38.00 TSS .26(.15)
c
 -.02, .55 .07 
Prestano et al. (2008) 6 16.00 MUL Outpatient Other/GRP PA WK4/WK104 25.00 CAPAS .07(.81)ab -1.52, 1.65 .93 
Satir (2012) 6 26.90 AN Outpatient Multi/IND PA 5/24 14.29 WAI -.20(.50)b -1.17, .78 .69 
Simpson et al. (2005) 6 32.00 BN Outpatient CBT/IND PA 4/17 0 ARM -.38(.77)b -1.88, 1.13 .63 
Sly et al. (2013) 78 27.73 AN Inpatient Other/IND PA WK4/VAR 0 WAI .23(.11)c .02, .45 .03 
Tasca & Lampard (2012) 127 26.11 MUL Outpatient Multi/GRP PA WK4/WK12 28.00 CAPAS .16(.08)c -.01, .32 .06 
Thompson-Brenner (2013) 36 25.63 BN Outpatient CBT/IND PA 3-5/20 24.00 WAI -.52(1.02)c -2.52, 1.48 .61 
Waller et al.(2012) 44 27.20 MUL Outpatient CBT/IND PA 6/6 14.00 WAI .18(.02)c .15, .21 < .01 
Zaitsoff et al.(2008)(A) 33 11.25 BN Outpatient FBT/IND PA 10/20 11.25 HRQ -.39(.18)ac -.74, -.04 .03 
Zaitsoff et al.(2008)(B) 29 11.25 BN Outpatient SPT/IND PA 10/20 11.25 HRQ .35(.19)ac -.02, .72 .07 
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Note.  ȕ &,>@z = 4.38, p < .0001; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; 
BN = bulimia nervosa; MUL = multiple eating disorder diagnoses; MIX = multiple settings; CBT = cognitive behavioral therapy; IPT = 
interpersonal psychotherapy; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = supportive psychotherapy; IND = individual; 
GRP = group; PA = patient; IO = independent observer; VAR = varied; MDN = median;  MO = months; WK = week; HAQ = Helping Alliance 
Questionnaire; WAI = Working Alliance Inventory;  SOFTA = System for Observing Family Alliances; TSS = Treatment Satisfaction Scale; 
CAPAS =  The California Psychotherapy Alliance Scales; ARM = Agnew Relationship Measure; HRQ = Helping Relationship Questionnaire; CI = 
confidence interval.   
aThe baseline measure of the outcome was not included in the regression analysis due to multicolinearity.  
b
The study effect size was based on total sample analyses. 
c
The study effect size was based on pairwise regression analyses. 
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Table 2. Results of random-effects moderator analyses 
 
Does early change in 
treatment outcome 
predict early/mid 
alliance? 
 
Does early/mid 
alliance predict 
subsequent symptom 
change? 
 Does early/mid 
alliance predict 
subsequent symptom 
change above and 
beyond early 
symptoms change? 
Moderator variable Q df P  Q df p  Q df p 
Therapy type 1.56 3 .67  10.61 4 .03  5.89 3 .12 
Mean age 2.77 1 .10  1.03 1 .31  16.20 1 < .01 
Eating disorder diagnosis .07 2 .97  .60 3 .90  6.10 2 .047 
Alliance rater .01 1 .93  .25 1 .62  1.53 1 .22 
Study drop-out rate 3.65 1 .06  .63 1 .43  .95 1 .33 
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Table 3. Question 2:  Does mid-to-end of treatment change in symptoms predict later alliance? 
 Moderator variables  Effect size information 
Report N Mean 
age DX 
Therapy 
setting 
Therapy 
type/mode 
Alliance  
rater/session 
Study 
drop-out 
(%) 
Alliance 
rating 
measure 
ȕSE) 95% CI p 
Brown et al. (2013) 33 25.70 AN Outpatient CBT/IND  PA/EOT 32.31 WAI .03(.21)b -.39, .44 .90 
Fluckiger et al. (2011)(A) 29 45.93 BED Outpatient CBT/IND PA/EOT 29.00 BPSRP -.06(.20)a -.44, .33 .77 
Fluckiger et al. (2011)(B) 26 45.93 BED Outpatient BWLT/IND PA/EOT 29.00 BPSRP .07(.21)a -.33, .48 .73 
Isserlin & Couturier (2012) 14 14.00 AN Outpatient FBT/IND IO/EOT 42.86 SOFTA .26(.22)b -.17, .69 .23 
Prestano et al. (2008) 6 16.00 MUL Outpatient Other/GRP PA/EOT 25.16 CAPAS .37(.49)a -.59, 1.33 .45 
Simpson et al. (2005) 6 32.00 BN Outpatient CBT/IND PA/EOT 0 ARM .41(.60)a -.77, 1.59 .50 
Tasca & Lampard (2012) 65 26.11 MUL Outpatient Multi/GRP PA/EOT 28.00 CAPAS .17(.13)b -.10, .43 .22 
Tasca et al. (2013) 49 44.30 BED Outpatient IPT/GRP PA/EOT 18.00 CAPAS .12(.19)b -.24, .48 .52 
Zaitsoff et al.(2008)(A) 28 16.10 BN Outpatient FBT/IND PA/EOT 11.25 HRQ .02(.21)b -.40, .43 .93 
Zaitsoff et al.(2008)(B) 24 16.10 BN Outpatient SPT/IND PA/EOT 11.25 HRQ -.26(.52)b -1.28, .76 .62 
Note.   ȕ &,>-.04, .24], z = 1.46, p =  .15.; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia 
nervosa; BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral 
therapy; IPT = interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-
based therapy; SPT = supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; EOT = end of 
treatment; WAI=Working Alliance Inventory; BPSRP=Bern Post-Session Reports for Patients;  SOFTA = System for Observing Family 
Therapy Alliances;  CAPAS =  The California Psychotherapy Alliance Scales;  ARM = Agnew Relationship Measure;  HRQ = Helping 
Relationship Questionnaire; CI = confidence interval.  
a
The study effect size was based on total sample analyses. 
b
The study effect size was based on pairwise regression analyses. 
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Table 4. Question 3: Does change in symptoms across treatment predict later alliance? 
 Moderator variables  Effect size information 
Report N Mean 
age DX 
Therapy 
setting 
Therapy 
type/mode 
Alliance 
rater/ 
session 
Study 
drop-out 
(%) 
Alliance 
rating 
measure 
ȕSE) 95% CI p 
Brown et al. (2013) 31 25.70 AN Outpatient CBT/IND  PA/EOT 32.31 WAI .11(.21)c -.29, .51 .58 
Fluckiger et al. (2011)(A) 29 45.93 BED Outpatient CBT/IND PA/EOT 29.00 BPSRP .17(.20)b -.21, .56 .37 
Fluckiger et al. (2011)(B) 26 45.93 BED Outpatient BWLT/IND PA/EOT 29.00 BPSRP .17(.21)b -.23, .58 .41 
Isserlin & Couturier (2012) 14 14.00 AN Outpatient FBT/IND IO/EOT 42.86 SOFTA .38(.26)c -.12, .89 .14 
Mander et al. (2013) 39 27.70 AN Inpatient Multi/MIX PA/EOT 28.00 SACiP .21(.17)b -.12, .54 .21 
Mitchell et al. (2008)(A) 35 29.60 BN Outpatient CBT/IND PA/EOT 37.50 WAI .57(.29)c .01, 1.13 .05 
Mitchell et al. (2008)(B) 36 28.40 BN Outpatient CBT/IND PA/EOT 37.50 WAI .09(.45)ac -.80, .98 .85 
Prestano et al. (2008) 6 16.00 MUL Outpatient Other/GRP PA/EOT 25.00 CAPAS .42(.66)ab -.87, 1.71 .52 
Simpson et al. (2005) 6 32.00 BN Outpatient CBT/IND PA/EOT 0 ARM .06(.55)b -1.01, 1.13 .91 
Stiles-Shields et al. (2013)(A) 24 33.40 AN Outpatient CBT/IND PA/EOT 22.58 HAQ .66(.19)c .29, 1.04 < .01 
Stiles-Shields et al. (2013)(B) 28 33.40 AN Outpatient SSCT/IND PA/EOT 12.50 HAQ .33(.20)c -.06, .72 .10 
Tasca & Lampard (2012) 65 26.11 MUL Outpatient Multi/GRP PA/EOT 28.00 CAPAS .20(.13)c -.06, .46 .13 
Tasca et al.(2007)(A) 38 43.86 BED Outpatient CBT/GRP PA/EOT 22.73 CAPAS .08(.20)c -.30, .47 .68 
Tasca et al.(2007)(B) 52 43.86 BED Outpatient IPT/GRP PA/EOT 22.73 CAPAS -.20(.15)c -.50, .10 .19 
Tasca et al. (2013) 72 44.30 BED Outpatient IPT/GRP PA/WK16 18.00 CAPAS .12(.13)c -.14, .39 .35 
Thompson-Brenner et al. (2013) 37 25.63 BN Outpatient CBT/IND PA/14-EOT 24.00 WAI .42(.24)c -.05, .89 .08 
Zaitsoff et al.(2008)(A) 29 16.10 BN Outpatient FBT/IND PA/EOT 11.25 HRQ .14(.20)ac -.24, .52 .49 
Zaitsoff et al.(2008)(B) 31 16.10 BN Outpatient SPT/IND PA/EOT 11.25 HRQ -.32(.19)ac -.69, .06 .10 
Note.   ȕ &,>@z = 2.96, p = .003; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia 
nervosa; BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral 
therapy; IPT = interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-
based therapy; SPT = supportive psychotherapy; SSCT= specialist supportive clinical management; IND = individual; GRP = group; PA = 
patient; IO = independent observer; WK = week;  EOT = end of treatment;  WAI=Working Alliance Inventory;  BPSRP=Bern Post-
Session Reports for Patients;  SOFTA = System for Observing Family Therapy Alliances; SACiP = Scale for the Multiperspective 
Assessment of General Change Mechanisms in Psychotherapy;  CAPAS =  The California Psychotherapy Alliance Scales;  ARM = Agnew 
Relationship Measure; HAQ = Helping Alliance Questionnaire;  HRQ = Helping Relationship Questionnaire; CI = confidence interval. 
aThe baseline measure of the outcome was not included in the regression analysis due to multicolinearity. 
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b
The study effect size was based on total sample analyses. 
c
The study effect size was based on pairwise regression analyses. 
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Table 5. Question 4a: Does early/mid alliance predict subsequent change in symptoms? 
  Moderator variables  Effect size information 
Report N Mean 
age DX 
Therapy 
setting 
Therapy 
type/mode 
Alliance 
rater 
 
Session/ 
of Total 
Study 
drop-
out 
(%) 
Alliance 
rating 
measure 
ȕSE) 95% CI p 
Bourion-Bedes et al. (2013)(A) 66 15.30 AN Inpatient Multi/IND PA 3/VAR 0 HAQ .27(.12)a .04, .51 .02 
Bourion-Bedes et al. (2013)(B) 42 15.30 AN Outpatient Multi/IND PA 3/VAR 0 HAQ .35(.16)a .04, .66 .03 
Brown et al. (2013) 33 25.70 AN Outpatient CBT/IND  PA 6/30-40 32.31 WAI -.25(.15)b -.54, .05 .10 
Constantino et al. (2005)(A) 72 28.10 BN Outpatient CBT/IND PA 12/19 25.91 HAQ .11(.11)b -.10, .32 .31 
Constantino et al. (2005)(B) 76 28.10 BN Outpatient IPT/IND PA 12/19 25.91 HAQ -.05(.08)b -.21, .12 .56 
Fluckiger et al. (2011)(A) 29 45.93 BED Outpatient CBT/IND PA 6/22 29.00 BPSRP .13(.16)a -.25, .51 .51 
Fluckiger et al. (2011)(B) 26 45.93 BED Outpatient BWLT/IND PA 6/22 29.00 BPSRP -.03(.22)a -.45, .40 .90 
Forsberg et al. (2013)(A) 40 14.80 AN Outpatient AFT/IND IO 3-5/20 17.36 WAI .13(.16)a -.18, .44 .41 
Forsberg et al. (2013)(B) 38 14.00 AN Outpatient FBT/IND IO 3-5/20 17.36 WAI .23(.16)a -.09, .55 .16 
Isserlin & Couturier (2012) 13 14.00 AN Outpatient FBT/IND IO 3/ MDN=12 42.86 
SOFTA 
.25(.33)b -.40, .90 .46 
Paulson Karlsson et al. (2013) 47 23.90 AN  MIX Multi/MIX PA MO6/ MO18±19 38.00 
TSS 
.21(.15)b -.09, .50 .18 
Mander et al. (2013) 39 27.70 AN Inpatient Multi/MIX PA DAY1/M= DAY48.8 28.00 
SACiP 
.37(.17)a .04, .70 .03 
Prestano et al. (2008) 6 16.00 MUL Outpatient Other/GRP PA WK4/ WK104 25.00 
CAPAS 
.59(.77)a -.93, 2.01 .45 
Simpson et al. (2005) 6 32.00 BN Outpatient CBT/IND PA 4/17 0 ARM -.56(.60)a -1.74, 
.62 .35 
Sly et al. (2013) 78 27.73 AN Inpatient Other/IND PA WK4/ VAR 0 
WAI 
-.10(.13)b -.35, .15 .44 
Tasca & Lampard (2012) 89 26.11 MUL Outpatient Multi/GRP PA WK4/ WK12 28.00 
CAPAS 
.13(.09)b -.04, .30 .14 
Tasca et al. (2013) 50 44.30 BED Outpatient IPT/GRP PA WK4/ WK16 18.00 
CAPAS 
.26(.11)b .05, .48 .02 
Zaitsoff et al.(2008)(A) 28 16.10 BN Outpatient FBT/IND PA 10/20 11.25 HRQ .45(.20)b .06, .84 .03 
Zaitsoff et al.(2008)(B) 26 16.10 BN Outpatient SPT/IND PA 10/20 11.25 HRQ .14(.20)b -.26, .54 .50 
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE  
Note.    ȕ &,>@z = 3.10, p = .002; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; 
BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral therapy; IPT = 
interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = 
supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; VAR = varied; MDN = median; MO = month; 
DAYS = days; WK = week;  HAQ = Helping Alliance Questionnaire;  WAI=Working Alliance Inventory;  BPSRP = Bern Post-Session Reports for 
Patients;  SOFTA = System for Observing Family Therapy Alliances;  TSS = Treatment Satisfaction Scale;  SACiP = Scale for the Multiperspective 
Assessment of General Change Mechanisms in Psychotherapy;  CAPAS =  The California Psychotherapy Alliance Scales;  ARM = Agnew 
Relationship Measure;  HRQ = Helping Relationship Questionnaire; CI = confidence interval.  
a
The study effect size was based on total sample analyses. 
b
The study effect size was based on pairwise regression analyses. 
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Table 6. Question 4b: Does early/mid alliance predict subsequent change in symptoms above and beyond early change in symptoms? 
  Moderator variables  Effect size information 
Report N Mean 
age DX 
Therapy 
setting 
Therapy 
type/mode 
Alliance 
rater 
 
Session/ 
of Total 
Study 
drop-
out (%) 
Alliance 
rating 
measure  
ȕSE) 95% CI p 
Bourion-Bedes et al. (2013)(A) 66 15.30 AN Inpatient Multi/IND PA 3/VAR 0 HAQ .31(.11)a .09, .52 .01 
Bourion-Bedes et al. (2013)(B) 42 15.30 AN Outpatient Multi/IND PA 3/VAR 0 HAQ .27(.14)a -.01, .55 .05 
Brown et al. (2013) 33 25.70 AN Outpatient CBT/IND  PA 6/30-40 32.31 WAI -.14(.19)b -.52, .23 .46 
Constantino et al. (2005)(A) 72 28.10 BN Outpatient CBT/IND PA 12/19 25.91 HAQ -.15(.12)b -.39, .09 .21 
Constantino et al. (2005)(B) 76 28.10 BN Outpatient IPT/IND PA 12/19 25.91 HAQ -.20(.12)b -.43, .03 .09 
Forsberg et al. (2013)(A) 40 14.80 AN Outpatient AFT/IND IO 3-5/32 17.36 WAI .17(.16)a -.14, .47 .28 
Forsberg et al. (2013)(B) 38 14.00 AN Outpatient FBT/IND IO 3-5/20 17.36 WAI .25(.18)a -.10, .60 .16 
Isserlin & Couturier (2012) 13 14.00 AN Outpatient FBT/IND IO 3/ MDN=12 42.86 
SOFTA 
.30(.34)b -.36, .96 .37 
Paulson Karlsson et al. (2013) 47 23.90 AN  MIX Multi/MIX PA MO6/ MO18±19 38.00 
TSS 
.19(.15)b -.11, .50 .21 
Prestano et al. (2008) 6 16.00 MUL Outpatient Other/GRP PA WK4/ WK104 25.00 
CAPAS 
-.07(.77)a -.82, .69 .86 
Simpson et al. (2005) 6 32.00 BN Outpatient CBT/IND PA 4/17 0 ARM -.35(.42)a -1.18, .48 .41 
Sly et al. (2013) 78 27.73 AN Inpatient Other/IND PA 4/VAR 0 WAI -.07(.12)b -.31, .16 .53 
Tasca & Lampard (2012) 89 26.11 MUL Outpatient Multi/GRP PA WK4/ WK12 28.00 
CAPAS 
.07(.11)b -.13, .28 .48 
Zaitsoff et al.(2008)(A) 28 16.10 BN Outpatient FBT/IND PA 10/20 11.25 HRQ -.03(.21)b -.43, .37 .88 
Zaitsoff et al.(2008)(B) 26 16.10 BN Outpatient SPT/IND PA 10/20 11.25 HRQ .28(.20)b -.11, .68 .16 
Note.    ȕ &,>-.04, .17], z = 1.26, p = .21;  A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; 
BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral therapy; IPT = 
interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = 
supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; VAR = varied; MDN = median; MO = 
month; WK = week;  HAQ = Helping Alliance Questionnaire;  WAI=Working Alliance Inventory;  HAQ = Helping Alliance Questionnaire;  
SOFTA = System for Observing Family Therapy Alliances;  TSS = Treatment Satisfaction Scale; CAPAS =  The California Psychotherapy 
Alliance Scales;  ARM = Agnew Relationship Measure;  HRQ = Helping Relationship Questionnaire; CI = confidence interval.  
a
The study effect size was based on total sample analyses. 
b
The study effect size was based on pairwise regression analyses. 
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE  
 
